Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Shares Outstanding for 10 consecutive years, with $67.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 7.72% to $67.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.2 million, a 7.72% increase, with the full-year FY2025 number at $67.2 million, up 7.72% from a year prior.
  • Shares Outstanding was $67.2 million for Q4 2025 at Rhythm Pharmaceuticals, up from $66.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $67.2 million in Q4 2025 to a low of $50.2 million in Q1 2021.
  • A 5-year average of $57.7 million and a median of $58.0 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: grew 13.87% in 2021, then grew 0.38% in 2022.
  • Rhythm Pharmaceuticals' Shares Outstanding stood at $50.3 million in 2021, then rose by 12.59% to $56.6 million in 2022, then grew by 4.97% to $59.4 million in 2023, then rose by 4.99% to $62.4 million in 2024, then rose by 7.72% to $67.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Shares Outstanding are $67.2 million (Q4 2025), $66.7 million (Q3 2025), and $63.9 million (Q2 2025).